Bluejay Diagnostics Stock (NASDAQ:BJDX)

Ownership Financials Chart

Previous Close

$2.03

52W Range

$1.70 - $40.80

50D Avg

$2.64

200D Avg

$5.50

Market Cap

$898.01K

Avg Vol (3M)

$237.66K

Beta

0.72

Div Yield

BJDX Company Profile

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 10, 2021

Website

BJDX Performance

BJDX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-7.17M	$-10.31M
Net Income	$-6.85M	$-7.72M	$-9.95M
EBITDA	-	$-6.70M	$-9.17M
Basic EPS	$-15.25	$-456.76	$-290.48
Diluted EPS	$-15.25	$-456.76	$-290.48

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
MSPR	MSP Recovery, Inc.
WINT	Windtree Therapeutics, Inc.
WGS	GeneDx Holdings Corp.
TIVC	Tivic Health Systems, Inc.
MLEC	Moolec Science S.A.
ELAB	PMGC Holdings Inc.